Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02159365
Title Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

multiple myeloma

Therapies

Dexamethasone + Elotuzumab + Lenalidomide

Age Groups: adult
Covered Countries USA


No variant requirements are available.